![]() |
產(chǎn)地 | 進口、國產(chǎn) |
品牌 | 上海莼試 |
保存條件 | Store at -20 °C |
貨號 | CS11174 |
應(yīng)用范圍 | WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
CAS編號 | |
抗體名 | Anti-Phospho-RSK3 (Thr353/356) |
克隆性 | |
靶點 | 詳見說明書 |
適應(yīng)物種 | 詳見說明書 |
形態(tài) | 詳見說明書 |
宿主 | 詳見說明書 |
亞型 | IgG |
標識物 | 詳見說明書 |
濃度 | 1mg/1ml% |
免疫原 | KLH conjugated Synthesised phosphopeptide derived from human RSK3 around the phosphorylation site of Thr353/356 |
產(chǎn)品訂購信息:
英文名稱 Anti-Phospho-RSK3 (Thr353/356)
中文名稱 磷酸化核糖體蛋白S6激酶家族RSK3抗體規(guī)格
別 名 p90RSK 2; pp90RSK 3; Ribosomal S6 kinase 3; RSK 3 antibody S6K alpha 2; S6K alpha; 90 kDa ribosomal protein S6 kinase 2; HU 2; MAP kinase activated protein kinase 1c; MAPKAPK1C; RPS6KA2; KS6A2_HUMAN.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Cow, Horse, Sheep, Guinea Pig
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 細胞生物 免疫學 信號轉(zhuǎn)導(dǎo) 細胞凋亡 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶
蛋白分子量 predicted molecular weight: 83kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human RSK3 around the phosphorylation site of Thr353/356
亞 型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化核糖體蛋白S6激酶家族RSK3抗體規(guī)格 產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 RSK3(Ribosomal S6 kinase 3)is a member of a family of 90-kDa ribosomal protein S6 kinases, which includes Rsk1, Rsk2 and Rsk3. These are broadly expressed serine/threonine protein kinases that are activated in response to mitogenic stimuli, including extracellular signal-regulated protein kinases Erk1 and Erk2. Rsk3 is a distinct isoform of p90Rsk that translocates to the cell nucleus, phosphorylates potential nuclear targets and may have a unique upstream activator. Several sites, such as Ser380, Thr359, Ser363 and Thr573, are important for its activation. Active Rsks appear to play a major role in transcriptional regulation by translocating to the nucleus and phosphorylating c Fos and CREB.
Function : Serine/threonine-protein kinase that acts downstream ofERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenicand stress-induced activation of transcription factors, regulatestranslation, and mediates cellular proliferation, survival, anddifferentiation. May function as tumor suppressor in epithelialovarian cancer cells.
Subunit : Forms a complex with either MAPK1/ERK2 or MAPK3/ERK1 inquiescent cells. Transiently dissociates following mitogenicstimulation (By similarity).
Subcellular Location : Nucleus. Cytoplasm.
Tissue Specificity : Widely expressed with higher expression inlung, skeletal muscle, brain, uterus, ovary, thyroid and prostate.
Post-translational modifications : Activated by phosphorylation at Ser-218 by PDPK1.Autophosphorylated on Ser-377, as part of the activation process.May be phosphorylated at Thr-356 and Ser-360 by MAPK1/ERK2 andMAPK3/ERK1 (By similarity).
N-terminal myristoylation results in an activated kinase inthe absence of added growth factors (By similarity).
Similarity : Belongs to the protein kinase superfamily. AGC Ser/Thrprotein kinase family. S6 kinase subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 2 protein kinase domains.
Database links : UniProtKB/Swiss-Prot: Q15349.2
IL-6 (Interleukin-6) Human 白介素6Multi-class antibodies規(guī)格: 0.5mg
Anti-DRADA (N terminal) 雙鏈RNA腺苷酸脫氨基酶抗體(N端)Multi-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh phospho-CDC27/ANAPC3(Ser427) 磷酸化后期促進復(fù)合蛋白3抗體 規(guī)格 0.1ml
產(chǎn)品名稱 規(guī)格 備注
WASF2 英文名稱: WASF2抗體 0.2ml
DDX3 英文名稱: 三磷酸腺苷依賴解旋酶DDX3抗體 0.2ml
Anti-DRADA (N terminal) 雙鏈RNA腺苷酸脫氨基酶抗體(N端)Multi-class antibodies規(guī)格: 0.2ml
Anti-PI3 Kinase p110 delta/FITC 熒光素標記磷脂酰肌醇激酶催化亞單位D抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rabbit Anti-mouse IgG-Fc 兔抗小鼠IgG-Fc (親和層析純化)Multi-class antibodies規(guī)格: 1mg
G蛋白偶合受體激酶1抗體 Anti-GRK1 0.2ml
Mouse Anti-Bov IgG/PE-Cy7 PE-Cy7標記的小鼠抗IgG 0.1ml
FRMD3 英文名稱: FRMD3蛋白抗體 0.1ml
Rhesus antibody Rh Phospho-SEK1/MKK4 (Thr261) 磷酸化原活化蛋白激酶激酶4抗體 規(guī)格 0.1ml
Rabbit Anti-mouse IgG-Fc 兔抗小鼠IgG-Fc (親和層析純化)Multi-class antibodies規(guī)格: 1mg
SNAPIN 英文名稱: 突觸相關(guān)蛋白25結(jié)合蛋白抗體 0.1ml
ELL2 英文名稱: 聚合酶延伸因子2抗體 0.2ml
膽囊收縮素抗體/縮膽囊素抗體(八肽) Anti-CCK8 0.1ml
Anti-UMOD/FITC 熒光素標記UMOD蛋白抗體IgGMulti-class antibodies規(guī)格: 0.2ml
Rhesus antibody Rh Phospho-Histone H2A.X (Ser139) 磷酸化組蛋白H2AX抗體 規(guī)格 0.1ml
CD105/Endoglin/TGF- Beta receptor CD105/轉(zhuǎn)化生長因子β受體抗原Multi-class antibodies規(guī)格: 0.5mg
RN-s, 大鼠紋狀體神經(jīng)元
SK-OV-3 人卵巢腺癌細胞
ITGA6 & ITGB1 Others Human 人 ITGA6 & ITGB1 Heterodimer 人細胞裂解液 (陽性對照)
CL-0312293ET(人胚腎細胞(SV40T和EBNA1基因修飾細胞))5×106cells/瓶×2
人神經(jīng)束膜細胞總RNAHPC NA
人上皮樣細胞;BEAS-2B 人卵巢上皮細胞完全培養(yǎng)基 100mL
CL-0160Molt-4(人急性淋巴母細胞細胞)5×106cells/瓶×2
HA Others H1N1 甲型 H1N1 (A/California/04/2009) 血凝素 (Hemagglutinin / HA) 桿狀病毒-昆蟲細胞裂解液 (陽性對照)
人主動脈平滑肌細胞裂解物HASMCL
SK-HEP-1細胞,人細胞 人低轉(zhuǎn)移細胞,95-C細胞 腦動脈內(nèi)皮細胞Many types of cells包裝:5 × 105次方(1ml)
兔主動脈平滑肌細胞;CCC-SMC-1
TIMP1 Others Human 人 TIMP-1 / TIMP1 人細胞裂解液 (陽性對照)
磷酸化核糖體蛋白S6激酶家族RSK3抗體規(guī)格 RN-s, 大鼠紋狀體神經(jīng)元
SK-OV-3 人卵巢腺癌細胞
ITGA6 & ITGB1 Others Human 人 ITGA6 & ITGB1 Heterodimer 人細胞裂解液 (陽性對照)
CL-0312293ET(人胚腎細胞(SV40T和EBNA1基因修飾細胞))5×106cells/瓶×2
人神經(jīng)束膜細胞總RNAHPC NA
人上皮樣細胞;BEAS-2B 人卵巢上皮細胞完全培養(yǎng)基 100mL
抗體的生物素化標記實驗要點:
1. 磷酸化核糖體蛋白S6激酶家族RSK3抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當則影響標記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件;
3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等;
5.當游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性;
6.生物素還可能與不同的功能基團,如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用;
8.在細胞的熒光標記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細胞可導(dǎo)致高本底。
抗體的鑒定:
1)磷酸化核糖體蛋白S6激酶家族RSK3抗體規(guī)格 抗體的效價鑒定:不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。
2)抗體的特異性鑒定:抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力。抗體的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3)抗體親和力:是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol??贵w親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。